Home

Case Study

How Covid-19 has Changed the eCOA/ePRO Landscape

How Covid-19 has Changed the eCOA/ePRO Landscape

YPrime
Pages 2 Pages

The disruption caused by the coronavirus pandemic necessitated significant changes to the way we all work and live. The pandemic also may be the catalyst to examining how we can quickly adapt to crises that impact the drug development industry and speed up adoption of technological tools to meet current and long-term needs.

Join for free to read

You Might Also Like


How COVID-19 has accelerated changes in the B2B sales landscape in Brazil
Report How COVID-19 has accelerated changes in the B2B sales landscape…
McKinsey & Company

COVID-19 CASE STUDY
Case Study COVID-19 CASE STUDY
SPIDR Tech

The COVID-19 Impact
Case Study The COVID-19 Impact
Solutionreach

A post–COVID-19 commercial-recovery strategy for B2B companies
White Paper A post–COVID-19 commercial-recovery strategy for B2B companies
McKinsey & Company

More from YPrime


Direct-to-Patient Solutions: Technology to Help Improve Patient Recruitment and Retention
Case Study Direct-to-Patient Solutions: Technology to Help Improve Patient…
YPrime

THE NEW GOLD STANDARDS OF IRT
Case Study THE NEW GOLD STANDARDS OF IRT
YPrime

Overcoming Clinical Trial Patient Recruitment and Retention Challenges
Case Study Overcoming Clinical Trial Patient Recruitment and Retention…
YPrime

Contentree Case Study
Case Study Contentree Case Study
YPrime
© 2025 Contentree.  All Rights Reserved   |   Privacy and Cookies   |   Legal   |   Do not sell my info